AU2002365938A1 - Modified antigen-presenting cells - Google Patents

Modified antigen-presenting cells

Info

Publication number
AU2002365938A1
AU2002365938A1 AU2002365938A AU2002365938A AU2002365938A1 AU 2002365938 A1 AU2002365938 A1 AU 2002365938A1 AU 2002365938 A AU2002365938 A AU 2002365938A AU 2002365938 A AU2002365938 A AU 2002365938A AU 2002365938 A1 AU2002365938 A1 AU 2002365938A1
Authority
AU
Australia
Prior art keywords
presenting cells
modified antigen
antigen
modified
presenting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002365938A
Other versions
AU2002365938A8 (en
Inventor
Marcus Butler
Naoto Hirano
Lee M. Nadler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2002365938A8 publication Critical patent/AU2002365938A8/en
Publication of AU2002365938A1 publication Critical patent/AU2002365938A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2002365938A 2001-11-20 2002-11-20 Modified antigen-presenting cells Abandoned AU2002365938A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33192801P 2001-11-20 2001-11-20
US60/331,928 2001-11-20
PCT/US2002/037123 WO2003065977A2 (en) 2001-11-20 2002-11-20 Modified antigen-presenting cells

Publications (2)

Publication Number Publication Date
AU2002365938A8 AU2002365938A8 (en) 2003-09-02
AU2002365938A1 true AU2002365938A1 (en) 2003-09-02

Family

ID=27734220

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002365938A Abandoned AU2002365938A1 (en) 2001-11-20 2002-11-20 Modified antigen-presenting cells

Country Status (4)

Country Link
EP (1) EP1458241A4 (en)
AU (1) AU2002365938A1 (en)
CA (1) CA2467893A1 (en)
WO (1) WO2003065977A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7955845B2 (en) * 2001-11-20 2011-06-07 Dana Farber Cancer Institute, Inc. Modified antigen-presenting cells
US7670781B2 (en) 2002-01-03 2010-03-02 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an agent that provides a primary activation signal and another agent that provides a co-stimulatory signal
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7638326B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
NZ627167A (en) 2003-10-16 2015-10-30 Stephen John Ralph Immunomodulating compositions and uses therefor
EP2295588B1 (en) 2004-05-27 2018-03-07 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses thefor
EP3535393B1 (en) 2016-11-07 2021-09-22 Genovie AB A two-part device for t-cell receptor synthesis and stable genomic integration to tcr-presenting cells
CN110036026B (en) * 2016-11-07 2024-01-05 杰诺维有限公司 Engineered two-part cell device for discovery and characterization of T cell receptor interactions with related antigens
EP4039800B1 (en) * 2016-11-07 2023-10-25 Genovie AB An engineered multi-component system for identification and characterisation of t-cell receptors and t-cell antigens

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69435010T2 (en) * 1993-04-20 2008-04-30 Hipler Partners Llp METHOD AND SUBSTANCES FOR THE TREATMENT OF INDIVIDUALS INFECTED WITH INTRA-CELLULAR INFECTIOUS AGENTS
AU2000243137A1 (en) * 2000-04-20 2001-11-07 Salvatore Albani Methods for isolation, quantification, characterization and modulation of antigen-specific t cells

Also Published As

Publication number Publication date
CA2467893A1 (en) 2003-08-14
AU2002365938A8 (en) 2003-09-02
WO2003065977A2 (en) 2003-08-14
WO2003065977A3 (en) 2003-12-11
WO2003065977A9 (en) 2003-10-16
EP1458241A4 (en) 2005-11-09
EP1458241A2 (en) 2004-09-22

Similar Documents

Publication Publication Date Title
AU2002368042A1 (en) Photovoltaic cell
AU2002317418A1 (en) Cell enumeration
AU2002357860A1 (en) Enzymes
AU2002366160A1 (en) Zinc-alkaline battery containing lambda-mn02
AU2002349713A1 (en) Nickel-hydrogen cell
AU2002347778A1 (en) Enzymes
AU2002365938A1 (en) Modified antigen-presenting cells
AU2002254161A1 (en) M cell directed vaccines
AU2002337150A1 (en) Microchamber
AU2002347898A1 (en) Whole cell assay
AU2002257273A1 (en) Enzymes
AU2002226571A1 (en) Biligands
AU2001100406A4 (en) DriverSMS
AUPR482001A0 (en) Metal-handling enzymes
AU2002236777A1 (en) Artificial antigen-presenting cells
AU2002257925A1 (en) Numberplates
AU2002222318A1 (en) Cell phone - hand set combination unit
AU2002346175A1 (en) Battery
AU2001100532A4 (en) FonePark
AU2002100746A4 (en) Adrail
AU2001100522A4 (en) e-Trans
AU2001100338A4 (en) Sunglove
AU2002247799A1 (en) Crusher
AUPR753701A0 (en) Berley macerator
AUPR257401A0 (en) Berley macerator

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase